Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 4/20 | 0.52 |
| ▸ | AURKA | O14965 | 2/20 | 0.52 |
| ▸ | PAK4 | O96013 | 2/20 | 0.52 |
| ▸ | IGF1R | P08069 | 7/20 | 0.51 |
| ▸ | NTRK1 | P04629 | 5/20 | 0.46 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | NUAK1 | O60285 | 1/20 | 0.42 |
| ▸ | PKN1 | Q16512 | 1/20 | 0.42 |
| ▸ | PAK3 | O75914 | 1/20 | 0.41 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.41 |
| ▸ | ULK1 | O75385 | 1/20 | 0.41 |
| ▸ | PDK1 | Q15118 | 1/20 | 0.41 |
| ▸ | ULK2 | Q8IYT8 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15216601 | 0.91 | NTRK1 (0.46) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15216604 | 0.90 | IGF1R (0.44) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15217663 | 0.85 | PAK1 (0.70) | PAK1AURKAPAK4IGF1RPKN1 | |
| SCHEMBL15208636 | 0.84 | PAK1 (0.75) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15209355 | 0.79 | PAK1 (0.53) | PAK1AURKAPAK4IGF1RPKN1 | |
| SCHEMBL15216594 | 0.77 | IGF1R (0.58) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15216608 | 0.77 | PAK1 (0.68) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15216505 | 0.77 | PAK1 (0.65) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15216461 | 0.76 | PAK1 (0.60) | PAK1AURKAPAK4IGF1RNTRK1 | |
| SCHEMBL15216468 | 0.76 | NTRK1 (0.62) | PAK1IGF1RNTRK1JAK2PAK3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-8637537-B2 | Serine/threonine kinase inhibitors | GENENTECH, INC. (US) | 2014-01-28 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | GENENTECH, INC. (US) | 2013-08-29 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130225620-A1 | SERINE/THREONINE KINASE INHIBITORS | PAK1, AKT1, RB1 | PAK1 1/4885AURKA 395/4885PAK4 22/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.